IP Library › Granted Patent US 9,364,519
Granted Patent B2
US 9,364,519 · App. 13/602,913 · Granted Jun 14, 2016

Pharmaceutical composition for use in the treatment of a neurodegenerative disease

Inventors: Sibylle Hess (Frankfurt am Main, DE); Christian Hoelscher (Northern Ireland, GB); Andrees Boehme (Paris, FR); Agnes Menut (Paris, FR); Laurent Pradier (Paris, FR); Veronique Taupin (Paris, FR)
Assignees: SANOFI-AVENTIS DEUTSCHLAND GMBH; UNIVERSITY OF ULSTER
A61K38/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,364,519
App. No.
13/602,913
Granted
Jun 14, 2016
Kind
B2
Abstract

The present application relates to a pharmaceutical composition for use in the prevention or/and treatment of a neurodegenerative disease, the composition comprising desPro 36 Exendin-4(1-39)-Lys 6 -NH 2 or/and a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, adjuvant, or/and auxiliary substance. In addition, the present application relates to the use of the pharmaceutical composition for the treatment and prevention of a neurodegenerative disease.

Claims (4)

1. A method for treating Alzheimer's disease in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising desPro 36 -Exendin-4(1-39)Lys 6 -NH 2 or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, adjuvant, auxiliary substance, or a combination thereof.

2. The method of claim 1 , wherein the progression of the Alzheimer's disease is slowed down.

3. The method according to claim 1 , wherein the Alzheimer's disease is an early-stage Alzheimer's disease.

4. The method of claim 1 , comprising administering desPro 36 Exendin-4(1-39)-Lys 6 -NH 2 or the pharmaceutically acceptable salt thereof in a daily dose selected from the range of 10 μg to 20 μg.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2013
From: HESS, SIBYLLE; HOELSCHER, CHRISTIAN; BOEHME, ANDREES; MENUT, AGNES; PRADIER, LAURENT; TAUPIN, VERONIQUE
To: SANOFI-AVENTIS DEUTSCHLAND GMBH; UNIVERSITY OF ULSTER
Reel/Frame 029687/0651 →
Priority Claims (1)
EP 11179784 · Sep 1, 2011 · regional
Continuity (2)
Provisional Application 61530146 · Sep 1, 2011
Related Publication 20130116179A1 · May 9, 2013